Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design

Barbara Hummel, Joerg Walden, Robert Stampfer, Sandra Dittmann, Benedikt Amann, Andrea Sterr, Martin Schaefer, Mark A Frye, Heinz Grunze

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Rationale and Objectives: Carbamazepine has shown reasonable antimanic properties, but its use has been limited because of enzyme-inducing effects. The keto-derivative oxcarbazepine (OXC) is very similar to carbamazepine, however, the metabolic pathway is different. OXC is not metabolized to the 10, 11-epoxide, which seems to be responsible for several undesirable side-effects of carbamazepine and furthermore OXC has less enzyme-inducing properties. Methods: In this non-random open label study, patients were treated with OXC for 14 days, crossed over to no OXC for 7 days, and then crossed back over to OXC for the remaining 14 days. OXC was titrated to a final dose in a range of 900-2100 mg due to individual response. Treatment success was defined as a reduction of the original Young Mania Rating Scale (YMRS) score of more than 50% at the end of study period. Results: Four of the 12 included patients (33%) met defined response criteria at the end of study period. Fifty percentage of the patients had to be prematurely excluded from the trial. The mean YMRS scores of the on-periods were obviously different from the off-period. Forty-two percentage of the patients experienced side-effects leading to premature discontinuation in two of 12 patients. Conclusion: Antimanic activity of OXC was demonstrated in this pilot study only for patients with mild or moderate manic symptoms. Further studies are encouraged to clarify OXC's role as mood-stabilizer and assess whether it has a profile similar to that of carbamazepine.

Original languageEnglish (US)
Pages (from-to)412-417
Number of pages6
JournalBipolar Disorders
Volume4
Issue number6
DOIs
StatePublished - Dec 2002
Externally publishedYes

Fingerprint

Antimanic Agents
Safety
Carbamazepine
Bipolar Disorder
oxcarbazepine
Epoxy Compounds
Enzymes
Metabolic Networks and Pathways

Keywords

  • Anticonvulsants
  • Bipolar disorder mania
  • Oxcarbazepine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Hummel, B., Walden, J., Stampfer, R., Dittmann, S., Amann, B., Sterr, A., ... Grunze, H. (2002). Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disorders, 4(6), 412-417. https://doi.org/10.1034/j.1399-5618.2002.02228.x

Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. / Hummel, Barbara; Walden, Joerg; Stampfer, Robert; Dittmann, Sandra; Amann, Benedikt; Sterr, Andrea; Schaefer, Martin; Frye, Mark A; Grunze, Heinz.

In: Bipolar Disorders, Vol. 4, No. 6, 12.2002, p. 412-417.

Research output: Contribution to journalArticle

Hummel, B, Walden, J, Stampfer, R, Dittmann, S, Amann, B, Sterr, A, Schaefer, M, Frye, MA & Grunze, H 2002, 'Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design', Bipolar Disorders, vol. 4, no. 6, pp. 412-417. https://doi.org/10.1034/j.1399-5618.2002.02228.x
Hummel, Barbara ; Walden, Joerg ; Stampfer, Robert ; Dittmann, Sandra ; Amann, Benedikt ; Sterr, Andrea ; Schaefer, Martin ; Frye, Mark A ; Grunze, Heinz. / Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. In: Bipolar Disorders. 2002 ; Vol. 4, No. 6. pp. 412-417.
@article{1330e10bbc904f8a96651321f72fd2a2,
title = "Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design",
abstract = "Rationale and Objectives: Carbamazepine has shown reasonable antimanic properties, but its use has been limited because of enzyme-inducing effects. The keto-derivative oxcarbazepine (OXC) is very similar to carbamazepine, however, the metabolic pathway is different. OXC is not metabolized to the 10, 11-epoxide, which seems to be responsible for several undesirable side-effects of carbamazepine and furthermore OXC has less enzyme-inducing properties. Methods: In this non-random open label study, patients were treated with OXC for 14 days, crossed over to no OXC for 7 days, and then crossed back over to OXC for the remaining 14 days. OXC was titrated to a final dose in a range of 900-2100 mg due to individual response. Treatment success was defined as a reduction of the original Young Mania Rating Scale (YMRS) score of more than 50{\%} at the end of study period. Results: Four of the 12 included patients (33{\%}) met defined response criteria at the end of study period. Fifty percentage of the patients had to be prematurely excluded from the trial. The mean YMRS scores of the on-periods were obviously different from the off-period. Forty-two percentage of the patients experienced side-effects leading to premature discontinuation in two of 12 patients. Conclusion: Antimanic activity of OXC was demonstrated in this pilot study only for patients with mild or moderate manic symptoms. Further studies are encouraged to clarify OXC's role as mood-stabilizer and assess whether it has a profile similar to that of carbamazepine.",
keywords = "Anticonvulsants, Bipolar disorder mania, Oxcarbazepine",
author = "Barbara Hummel and Joerg Walden and Robert Stampfer and Sandra Dittmann and Benedikt Amann and Andrea Sterr and Martin Schaefer and Frye, {Mark A} and Heinz Grunze",
year = "2002",
month = "12",
doi = "10.1034/j.1399-5618.2002.02228.x",
language = "English (US)",
volume = "4",
pages = "412--417",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "6",

}

TY - JOUR

T1 - Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design

AU - Hummel, Barbara

AU - Walden, Joerg

AU - Stampfer, Robert

AU - Dittmann, Sandra

AU - Amann, Benedikt

AU - Sterr, Andrea

AU - Schaefer, Martin

AU - Frye, Mark A

AU - Grunze, Heinz

PY - 2002/12

Y1 - 2002/12

N2 - Rationale and Objectives: Carbamazepine has shown reasonable antimanic properties, but its use has been limited because of enzyme-inducing effects. The keto-derivative oxcarbazepine (OXC) is very similar to carbamazepine, however, the metabolic pathway is different. OXC is not metabolized to the 10, 11-epoxide, which seems to be responsible for several undesirable side-effects of carbamazepine and furthermore OXC has less enzyme-inducing properties. Methods: In this non-random open label study, patients were treated with OXC for 14 days, crossed over to no OXC for 7 days, and then crossed back over to OXC for the remaining 14 days. OXC was titrated to a final dose in a range of 900-2100 mg due to individual response. Treatment success was defined as a reduction of the original Young Mania Rating Scale (YMRS) score of more than 50% at the end of study period. Results: Four of the 12 included patients (33%) met defined response criteria at the end of study period. Fifty percentage of the patients had to be prematurely excluded from the trial. The mean YMRS scores of the on-periods were obviously different from the off-period. Forty-two percentage of the patients experienced side-effects leading to premature discontinuation in two of 12 patients. Conclusion: Antimanic activity of OXC was demonstrated in this pilot study only for patients with mild or moderate manic symptoms. Further studies are encouraged to clarify OXC's role as mood-stabilizer and assess whether it has a profile similar to that of carbamazepine.

AB - Rationale and Objectives: Carbamazepine has shown reasonable antimanic properties, but its use has been limited because of enzyme-inducing effects. The keto-derivative oxcarbazepine (OXC) is very similar to carbamazepine, however, the metabolic pathway is different. OXC is not metabolized to the 10, 11-epoxide, which seems to be responsible for several undesirable side-effects of carbamazepine and furthermore OXC has less enzyme-inducing properties. Methods: In this non-random open label study, patients were treated with OXC for 14 days, crossed over to no OXC for 7 days, and then crossed back over to OXC for the remaining 14 days. OXC was titrated to a final dose in a range of 900-2100 mg due to individual response. Treatment success was defined as a reduction of the original Young Mania Rating Scale (YMRS) score of more than 50% at the end of study period. Results: Four of the 12 included patients (33%) met defined response criteria at the end of study period. Fifty percentage of the patients had to be prematurely excluded from the trial. The mean YMRS scores of the on-periods were obviously different from the off-period. Forty-two percentage of the patients experienced side-effects leading to premature discontinuation in two of 12 patients. Conclusion: Antimanic activity of OXC was demonstrated in this pilot study only for patients with mild or moderate manic symptoms. Further studies are encouraged to clarify OXC's role as mood-stabilizer and assess whether it has a profile similar to that of carbamazepine.

KW - Anticonvulsants

KW - Bipolar disorder mania

KW - Oxcarbazepine

UR - http://www.scopus.com/inward/record.url?scp=0347927722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347927722&partnerID=8YFLogxK

U2 - 10.1034/j.1399-5618.2002.02228.x

DO - 10.1034/j.1399-5618.2002.02228.x

M3 - Article

C2 - 12519102

AN - SCOPUS:0347927722

VL - 4

SP - 412

EP - 417

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 6

ER -